Comparing PARP Inhibitors: — Olaparib, Niraparib and Talazoparib

Switching between PARP inhibitors is not the same as swapping one blood pressure tablet for another. Each drug has specific approved indications, and a drug approved for your cancer type in one setting may not be appropriate in another. If you are having side effects or concerns about cost, discuss it with your oncologist — a dose adjustment, a supportive medicine, or a patient-access programme may address the problem without switching. Do not stop or change your drug on your own.

They are not directly comparable in that way. Each drug is evaluated for the specific cancer type and population it is approved for, and results from one setting do not tell you how either drug would perform in another. Talazoparib is considered a more potent PARP trapper at the molecular level, but laboratory potency does not translate directly into a better outcome for every patient. The drug your oncologist has prescribed is the one the evidence supports for your specific situation.

BRCA mutations are one way a tumour can lose the ability to repair certain DNA damage, but not the only way. A broader defect called homologous recombination deficiency, or HRD, covers more patients whose tumours have this repair weakness even without a BRCA mutation. In ovarian cancer maintenance, ESMO and NCCN guidelines include HRD-positive tumours as a group that may benefit from niraparib — which is why the BRCA requirement is not absolute for that indication. Your oncologist will have tested for this, or can tell you whether it applies.

Niraparib reduces platelets — the blood cells that help clotting — more commonly than the other two PARP inhibitors. This usually happens in the first months of treatment and is managed by checking blood counts regularly and reducing the dose when needed. A dose reduction is a planned part of using niraparib safely, not a failure. Tell your team if you notice unusual bruising, small red or purple spots under the skin, or bleeding that takes longer than usual to stop.

MDS (myelodysplastic syndrome) and AML (acute myeloid leukaemia) are rare but serious blood conditions that have been reported in patients on olaparib, particularly with long-term use. The absolute risk is low, and your oncologist will monitor your blood counts at regular intervals to watch for early signs. If blood counts fall in a pattern that concerns your team, they may investigate further. This is part of why keeping to your scheduled blood tests matters — it is the system that catches problems early.

Olaparib and niraparib are CDSCO-approved and available in India. Talazoparib's availability is more limited — ask your oncologist whether it is accessible for your situation. All three are expensive, and any cost figure you find online is dated. Indicative costs vary by dose and duration and should be discussed directly with your oncologist or a pharmacy that supplies oncology drugs. Some manufacturers offer patient-assistance programmes, and your oncologist or hospital social worker can help establish whether you qualify.